BioNTech's Twin Tracks: Factory Sell-Off Talks and a 2026 Cancer Filing Keep Investors on Edge

BioNTech restructures from COVID vaccines to oncology, closing four plants by 2026. Moderna may buy three German sites. Stock near €78.70, RSI neutral.

BioNTech is executing one of the most ambitious pivots in biotech — retreating from pandemic-era infrastructure while simultaneously betting big on oncology. The stock, which closed at €78.70 on Friday, reflects the market's caution: that's roughly eight percent below its 200-day moving average of €85.47 and 25 percent off the 52-week high. With an RSI of 50.4, momentum is neutral, but the underlying narrative is far from static.

The restructuring is taking tangible shape. BioNTech has confirmed plans to close its production sites in Marburg, Idar-Oberstein, Tübingen, and Singapore by the end of next year, affecting up to 1,860 positions. Now, rival Moderna has reportedly expressed interest in taking over three of the German factories. Moderna CEO Stéphane Bancel sees the facilities as a faster route to building European capacity than starting from scratch — though any deal would require the blessing of the German government. For BioNTech, a sale would align with the cost discipline that underpins its broader strategy: preserve the cash pile for clinical development. That pile stood at nearly €17 billion at the end of March, providing a multi-year runway for an extensive oncology pipeline.

Investors are also watching a separate capital allocation move. Since June 8, BioNTech has been running a share buyback programme of up to one billion US dollars in American Depositary Shares. The weekly announcement cycle provides a steady drip of demand, but the bigger catalysts lie in the clinic and the factory sale negotiations.

On the cancer front, the company is closing in on a historic milestone. BioNTech plans to file its first oncology marketing application in 2026, for the antibody-drug conjugate Trastuzumab Pamirtecan. The FDA has granted accelerated review, and the data justify the speed: in a Phase 2 study, nearly 48 percent of patients responded, and among those with high HER2 expression, the response rate jumped above 73 percent. That candidate targets a range of solid tumours, and if approved, would mark BioNTech's transition from pandemic play to precision oncology company.

Yet the transition comes at a cost. First-quarter research spending rose to €557 million, while revenue collapsed to just €118 million as demand for Covid vaccines continues to wane. The management team acknowledges that no oncology revenue will flow this year. Instead, the stock will be driven by clinical readouts — seven key data releases are scheduled for the second half of 2026 — and by the prospect of unlocking value from the factories. The next inflection point arrives on August 4, when BioNTech reports second-quarter earnings. While the numbers will again underscore the revenue gap, the market's attention will be on any update on the Moderna talks and on progress toward that 2026 FDA submission.